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Abstract
Background: Trials using mineralocorticoid receptor antagonists (MRAs) in myocar-
dial infraction (MI) without heart failure (HF) or systolic impairment have been under-
powered to assess morbidity-mortality benefit. In EPHESUS 6632 patients were
included, of whom 11% had an ejection fraction (EF) of 40% and HF or diabetes. We
aim to assess the potential benefit of MRAs in MI with EF of 40%.
Methods: Cox models with interaction term for EF. The primary outcome was a compos-
ite of cardiovascular death or hospitalization for cardiovascular reasons.
Hypothesis: Patients with an EF of 40% benefit similarly from MRA therapy to those
with an EF <40%.
Results: In EPHESUS, 753 patients had an EF = 40% and 5864 an EF < 40%. Patients
with an EF = 40% were younger (63 vs 64 years), had lower heart rate (73 vs 75 bpm),
less atrial fibrillation (10% vs 14%), previous MI (21% vs 28%), HF hospitalization (5%
vs 8%), and had more often reperfusion therapy and/or revascularization (55% vs
44%). The mean EF was 40.0 ± 0.3% in those with EF = 40% vs 32.2 ± 5.9% in those
with EF < 40%. The primary outcome occurred in 13.3% (10 events per 100 py) of the
patients with EF = 40% vs 22.9% (19 events per 100 py) in those with EF < 40%;
adjusted HR for EF = 40% vs <40% = 0.65 (0.53-0.81). Eplerenone reduced the event-
rate homogenously regardless of EF (interactionp EF = 40% vs EF < 40% = 0.21). Simi-
lar findings were observed for cardiovascular and all-cause death.
Conclusion: Eplerenone reduces hospitalizations and mortality in patients with MI
and EF = 40% similarly to patients with EF < 40%. These findings suggest that MI
patients with EF in the “mid-range zone” may also benefit from MRA therapy which
might help clinicians in their treatment decisions.
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1 | INTRODUCTION
Mineralocorticoid receptor antagonists (MRAs) have clear “IA” guide-
line indication for patients with a myocardial infraction (MI) and a left
ventricular ejection fraction (EF) inferior to 40% if accompanied by
signs and symptoms of heart failure (HF) or diabetes.1,2 Despite the
guideline recommendations, MRAs are prescribed in a small propor-
tion of these patients.3,4
In patients with an EF of 40% or greater, the potential benefit of
MRAs is unknown. A large proportion of patients with a recent MI
have a EF of 40% or greater regardless of having (or not) signs and
symptoms of HF. In the HF field, patients with an EF situated
between 40% and 50% have been called “mid-range” EF patients,1
and there is some evidence suggesting that they might benefit from
MRA therapy.5,6 However, in MI this specific population has not been
studied in dedicated trials using MRAs, and trials including patients
without HF at presentation have been underpowered to ascertain
morbidity-mortality benefit.7,8
In the Eplerenone, a Selective Aldosterone Blocker, in Patients
with Left Ventricular Dysfunction after Myocardial Infarction
(EPHESUS) trial,9 eplerenone reduced the relative rate of all-cause
death by 15% and the composite of death from cardiovascular causes
or hospitalization for cardiovascular events by 13%. In EPHESUS,
patients could be enrolled within 3 to 14 days after a MI, if they had
an EF ≤ 40% and HF or diabetes. In this large trial, it is thus possible
that many of these patients had an EF of 40% or greater due to a
“digit preference” for EF values in multiples of 5%, as it has been
described in previous reports that patients with EF between 35% and
45% are attributed to have an EF of 40%.10,11
We performed an analysis of the EPHESUS trial to assess the
characteristics, event-rates and the effect of eplerenone in patients
with EF = 40%, compared with those with EF < 40%.
2 | METHODS
2.1 | Study design, setting, and participants
EPHESUS included 6632 patients with an acute MI (3-14 days after
the MI), and a LVEF ≤ 40% plus HF or diabetes to receive either
eplerenone (25 mg per day initially, titrated to a maximum of 50 mg
per day) or placebo. Among all enrolled patients, 743 (11.2%) and an
EF = 40%, and only 10 had an EF > 40%. Therefore, we refer to these
patients as having an EF of 40%.
The primary end points were (a) a composite of death from cardio-
vascular causes or hospitalization for cardiovascular causes (including
HF, acute MI, stroke, or ventricular arrhythmia), and (b) death from
any cause. The median (percentile 25-75) follow-up time was 1.3
(1.0-1.7) years.9
EPHESUS was conducted in accordance with the Declaration of
Helsinki and approved by the site ethics committees. All participants
gave written informed consent to participate in the study.
2.2 | Study outcomes
In the present analysis, the primary outcome is a composite of cardio-
vascular death or cardiovascular hospitalization. Cardiovascular death
alone, all-cause death, and HF hospitalization were also assessed.
Hyperkalemia (defined as a potassium concentration above 5.5 mmol/l
at any time throughout the follow-up) and worsening renal function
(WRF, defined as a decline superior to 30% in the estimated glomerular
filtration rate at any time throughout the follow-up) were assessed as
major safety outcomes.
The outcomes were centrally adjudicated by endpoint committees
and defined by the conventional criteria.9
2.3 | Statistical analysis
Baseline clinical characteristics of patients were summarized by EF
groups (<40% vs 40%) using means and SD for continuous variables,
frequencies and percentages for categorical variables, and hazard
ratios (HRs), incidence rates, and incidence-rate differences with their
95% confidence interval (95%CI) for treatment effect estimates.
Time-to-first-event curves were obtained using the Kaplan-Meier
method and compared using the log-rank test. Univariate Cox propor-
tional hazards' modeling was used to explore the association between
EF and/or the intervention and the study outcomes, and a Cox model
with interaction term on EF was performed to assess the potential het-
erogeneity of the treatment effect by EF. We also performed adjusted
models for reducing the potential confounding of the associations
between EF and outcomes. The covariates for this multivariate model
were chosen according to their clinical relevance or historical associa-
tion with the outcome in the previous studies12-14 and included age,
sex, body mass index, heart rate, estimated glomerular filtration rate,
sodium, potassium, previous MI, peripheral vascular disease, previous
HF hospitalization, atrial fibrillation, diabetes, hypertension, chronic
obstructive pulmonary disease, angiotensin-converting-enzyme-inhibi-
tors/angiotensin-receptor blockers, beta-blockers, Q-wave MI, Killip
class, reperfusion therapy, and study drug (eplerenone or placebo). Pro-
portional hazards assumptions were tested based on Schoenfeld resid-
uals with time interaction.
All the statistical analyses were performed using the STATA/SE
software, version 15.1 (Stata Corp, College Station, Texas).
3 | RESULTS
3.1 | Patients' characteristics
In the present analysis, 753 patients had an EF = 40% and 5864 an
EF < 40%. Patients with EF = 40% were slightly younger (63 vs
64 years), had lower heart rate (73 vs 75 bpm), lower proportion of
atrial fibrillation (10 vs 14%), previous MI (21 vs 28%), HF hospitaliza-
tion (5 vs 8%), and had more often reperfusion therapy and/or revas-
cularization (55 vs 44%) (Table 1). The mean EF was 40.0 ± 0.3% in
those with EF = 40% vs 32.2 ± 5.9% in those with EF < 40%. Only
10 patients (0.1%) had an EF > 40% (Supporting Information Figure 1).
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3.2 | Events by left ventricular EF categories
Patients with an EF = 40% had lower event rates compared to
patients with an EF < 40%. The primary outcome occurred in 13.3%
of the patients with an EF = 40% vs 22.9% in those with an EF < 40%,
with corresponding event rates per 100 person-years of 10.3
(8.5-12.5) vs 19.2 (18.2-20.2). The adjusted HR (95%CI) for EF = 40%
when compared to patients with EF < 40% was 0.65 (0.53-0.81).
All cause-death occurred in 9.0% of the patients with an EF = 40%
vs 16.4% in those with an EF < 40%, with corresponding event rates
per 100 person-years of 6.6 (5.2-8.4) vs 12.6 (11.8-13.4). The
adjusted HR (95%CI) for EF = 40% compared with EF < 40% as refer-
ence was 0.65 (0.50-0.83). Consistent findings were observed for car-
diovascular death and HF hospitalization (Table 2).
3.3 | Treatment effect
Eplerenone (compared with placebo) reduced the event rates with
similar magnitude regardless of the EF, with relative reductions of the
primary outcome ranging from 2% to 56% in patients with EF = 40%
and 5% to 23% in patients with EF < 40%; p for interaction = 0.21.
TABLE 1 Baseline clinical features by EF categories
Characteristics EF < 40% EF = 40% p value
N 5864 753
Age, years 64.0 ± 11.5 63.1 ± 11.5 .031
Male sex 4164 (71.0%) 536 (71.2%) .92
White race 5287 (90.2%) 682 (90.6%) .42
Smoking 1800 (30.7%) 242 (32.2%) .69
SBP, mmHg 118.9 ± 16.5 120.3 ± 16.5 .028
DBP, mmHg 72.0 ± 10.7 72.8 ± 10.6 .067
Heart rate, bpm 74.9 ± 11.8 73.4 ± 10.7 <.001
BMI, kg/m2 27.4 ± 4.5 27.7 ± 4.6 .087
Diabetes 1895 (32.3%) 239 (31.7%) .75
Hypertension 3535 (60.3%) 460 (61.1%) .67
Atrial fibrillation 792 (13.5%) 78 (10.4%) .016
MI before index AMI 1637 (27.9%) 155 (20.6%) <.001
Angina 2453 (41.8%) 276 (36.7%) .007
Peripheral vascular disease 730 (12.4%) 89 (11.8%) .62
HFH before index AMI 464 (7.9%) 40 (5.3%) .011
COPD 553 (9.4%) 69 (9.2%) .81
eGFR, ml/min/1.73 m2 68.3 ± 20.9 69.3 ± 20.7 .21
Hemoglobin, g/dl 13.3 ± 1.7 13.3 ± 1.7 .99
Potassium, mmol/l 4.3 ± 0.5 4.3 ± 0.4 .30
Sodium, mmol/l 139.4 ± 4.2 140.0 ± 5.2 <.001
ACEI/ARB 5112 (87.2%) 627 (83.3%) .003
Beta-blocker 4359 (74.3%) 591 (78.5%) .014
Index Q-wave AMI 4153 (72.2%) 549 (73.8%) .37
Killip class I 846 (14.5%) 163 (21.7%) <.001
II 3800 (65.2%) 469 (62.5%)
III 995 (17.1%) 96 (12.8%)
IV 184 (3.2%) 23 (3.1%)
Reperfusion or revascularization 2585 (44.1%) 416 (55.2%) <.001
EF, % 32.2 ± 5.9 40.0 ± 0.3 <.001
Time from AMI to rand., days 7.3 ± 3.0 7.0 ± 3.1 .032
Eplerenone 2916 (49.7%) 397 (52.7%) .12
Duration of hosp. for index AMI, days 15.4 ± 10.2 13.9 ± 7.7 <.001
Abbreviations: ACE/ARB, angiotensin converting enzyme inhibitor or angiotensin receptor blocker; AMI, acute myocardial infarction; COPD, chronic
obstructive pulmonary disease; CV, cardiovascular; DBP, diastolic blood pressure; EF, left ventricular ejection fraction; eGFR, estimated glomerular
filtration rate calculated by the CKD-EPI formula; HF, heart failure; MI, myocardial infarction; SBP, systolic blood pressure.
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The effect of treatment was more imprecise in patients with EF = 40%
due to a smaller sample size/loss of statistical power. All the studied
outcomes pointed toward a benefit of eplerenone regardless of the
EF (Table 3 and Figure 1).
The effect of treatment was of higher absolute magnitude in the
early follow-up period (first 6 months), regardless of EF (Figure 2 and
Supporting Information Table 1). Proportional hazards assumptions
can be fairly assumed (proportional-hazards test based on Schoenfeld
residuals p-value in patients with an EF = 40% = 0.24 and in
EF < 40% = 0.13).
3.4 | Side effects
Hyperkalemia (K+ > 5.5 mmol/l) and WRF (defined as a decline in
eGFR > 30%) at any time throughout the follow-up, occurred similarly
between the eplerenone and placebo groups in patients with an
EF = 40% (hyperkalemia: 14.8% in eplerenone vs 13.1% in placebo;
p-value = 0.53, and WRF: 17.7% in eplerenone vs 15.8% in placebo;
p-value = 0.49). In patients with EF < 40% hyperkalemia and WRF
occurred more frequently in patients taking eplerenone (hyperkalemia:
15.9% in eplerenone vs 11.4% in placebo; p-value < .001, and WRF:
23.0% in eplerenone vs 19.5% in placebo; p-value = .001); but without
TABLE 2 Events by EF categories
Outcome N (%) events Event rates Crude HR (95%CI) p value Adj. HR (95%CI)a p value
Primary outcome
EF < 40% 1344 (22.9) 19.2 (18.2–20.2) Ref. <.001 Ref. <.001
EF = 40% 100 (13.3) 10.3 (8.5–12.5) 0.55 (0.44-0.67) 0.65 (0.53-0.81)
CV death
EF < 40% 833 (14.2) 10.9 (10.2-11.7) Ref. <.001 Ref. <.001
EF = 40% 52 (6.9) 5.0 (3.8-6.6) 0.47 (0.35-0.62) 0.58 (0.43-0.77)
All-cause death
EF < 40% 959 (16.4) 12.6 (11.8–13.4) Ref. <.001 Ref. .001
EF = 40% 68 (9.0) 6.6 (5.2–8.4) 0.53 (0.41-0.68) 0.65 (0.50–0.83)
HF hospitalization
EF < 40% 787 (13.4) 11.2 (10.5-12.0) Ref. <.001 Ref. .008
EF = 40% 64 (8.5) 6.6 (5.2–8.4) 0.60 (0.46-0.77) 0.70 (0.53-0.91)
Note: The primary outcome is a composite of cardiovascular death or cardiovascular hospitalization. Median follow-up time to death or censor = 1.3
(1.0-1.7) years. Event rates per 100 person-years.
Abbreviations: CV, cardiovascular; EF, left ventricular ejection fraction; HF, heart failure.
aModel adjusted on age, sex, body mass index, heart rate, estimated glomerular filtration rate, sodium, potassium, previous myocardial infarction, peripheral
vascular disease, previous heart failure hospitalization, atrial fibrillation, diabetes, hypertension, chronic obstructive pulmonary disease,
angiotensin-converting-enzyme-inhibitors/angiotensin-receptor blockers, beta-blockers, Q-wave myocardial infarction, Killip class, reperfusion therapy,
and study drug (eplerenone or placebo).
TABLE 3 Treatment effect by EF
categories
Outcome Event rates PBO Event rates EPL HR (95%CI) Interactionp
Primary outcome
EF < 40% 20.8 (19.3-22.4) 17.6 (16.2-19.0) 0.85 (0.77-0.95) 0.21
EF = 40% 12.7 (9.8-16.4) 8.3 (6.1-11.1) 0.66 (0.44-0.98)
CV death
EF < 40% 11.9 (10.9-13.1) 10.0 (9.0-11.0) 0.84 (0.73-0.96) 0.39
EF = 40% 6.2 (4.3-8.8) 4.0 (2.7-6.1) 0.66 (0.38-1.13)
All-cause death
EF < 40% 13.6 (12.5-14.9) 11.6 (10.6-12.7) 0.85 (0.75-0.97) 0.60
EF = 40% 7.6 (5.5-10.5) 5.7 (4.0-8.1) 0.75 (0.46-1.21)
HF hospitalization
EF < 40% 12.1 (11.0-13.3) 10.4 (9.4-11.5) 0.87 (0.75-1.00) 0.23
EF = 40% 8.2 (6.0-11.4) 5.2 (3–6-7.6) 0.63 (0.39-1.04)
Note: The primary outcome is a composite of cardiovascular death or cardiovascular hospitalization.
Median follow-up time to death or censor = 1.3 (1.0-1.7) years. Event rates per 100 person-years.
Abbreviations: CV, cardiovascular; EPL, eplerenone; HF, heart failure; LVEF, left ventricular ejection
fraction; PBO, placebo.
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statistically significant differences (interaction) by EF (inter-
actionp = 0.27 for hyperkalemia and = 0.72 for WRF).
4 | DISCUSSION
In EPHESUS, treatment with eplerenone (vs placebo) significantly
reduced the composite of time-to-first cardiovascular death or cardio-
vascular hospitalization, cardiovascular and all-cause death, and HF
hospitalization, regardless of the EF (40% vs <40%). These findings
support the use of eplerenone also in MI patients with EF of 40%.
In HF, patients enrolled in the Spironolactone for Heart Failure
with Preserved Ejection Fraction (TOPCAT) trial, who had a “mid-
range” EF, might have benefited more from spironolactone therapy.5,6
Notwithstanding, these HF patients were substantially different from
the MI patients enrolled in EPHESUS. To the best of our knowledge,
no study has demonstrated the efficacy of MRAs on morbidity-
mortality end-points in patients with a EF ≥ 40% in MI patients. The
role of MRAs in MI without systolic dysfunction or HF has been eval-
uated in two randomized controlled trials: the Early Aldosterone
Blockade in Acute Myocardial Infarction (ALBATROSS)8 and the Early
F IGURE 1 Forest plot with hazard ratios
and 95% confidence intervals and Kaplan-
Meier curves for the outcome of
cardiovascular death or cardiovascular
hospitalization by EF categories. P for
interaction by EF category (<40% vs
40%) = 0.21. The primary outcome is a
composite of cardiovascular death or
cardiovascular hospitalization. Median follow-
up time = 1.3 (1.0-1.7) years. EF, left
ventricular ejection fraction; EPL, eplerenone;
PBO, placebo
F IGURE 2 Smoothed hazard
estimates of the treatment effect over
time on the study primary outcome. The
treatment effect is more marked in the
early follow-up period, regardless of the
EF. The primary outcome is a composite
of cardiovascular death or cardiovascular
hospitalization. Median follow-up
time = 1.3 (1.0-1.7) years. EF, left
ventricular ejection fraction; EPL,
eplerenone; PBO, placebo
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Eplerenone Treatment in patients with acute ST-elevation Myocardial
Infarction without Heart Failure (REMINDER)7 trials. These trials dem-
onstrated the safety of MRA therapy in this setting but did not reduce
morbidity nor mortality, likely because the trials were underpowered
to assess the treatment effect in terms of major cardiovascular events
(such as death or hospitalizations). Consequently, until larger and ade-
quately powered trials are conducted, MRA therapy cannot be rou-
tinely advised in post-MI patients without systolic dysfunction and/or
HF. An individual patient-data meta-analysis of the ALBATROSS and
REMINDER trials pointed toward a potential mortality benefit of MRA
use in a MI population without HF, but even pooling these trials the
event rates was too low to draw any solid conclusions.15 Notwith-
standing, based on the findings depicted herein, MRAs could be con-
sidered in patients with a MI and an EF around 40%. The event rate
reduction is marked in the first few months of therapy initiation (and
may be maintained thereafter), this is of particular relevance because
MRAs may reduce the risk of sudden death in this “high-risk” post-MI
period were defibrillators are not indicated.14,16 The ongoing Colchi-
cine and Spironolactone in Patients With STEMI/SYNERGY Stent
Registry (CLEAR-SYNERGY) trial (ClinicalTrials.gov Identifier:
NCT03048825) may help in assessing the potential effect of MRAs in
patients with MI and an EF ≥ 40%.
In our study, and as previously documented,9 there was an
increased incidence of hyperkalemia and WRF among patients receiv-
ing eplerenone (additionally, our study suggests that these side effects
might have been experienced mainly by patients with an EF < 40%).
This finding underscores the need to measure serum potassium and
creatinine levels serially and to adjust the dose of eplerenone accord-
ingly. In EPHESUS, the protocol mandated “if at any time during the
study the serum potassium is >5.5 mEq/l but <6.0 mEq/l, the dose of
study drug will be reduced to the next lower dose level or temporarily
withheld if the patient is receiving 25 mg of eplerenone every other
day.9 In a renal function stratified analysis from the EMPHASIS-HF
trial, we found that a dose of 25 mg/day of eplerenone in patients
with eGFR <50 ml/min is as effective as 50 mg/day in patients with
eGFR ≥ 50 ml/min; these are the doses that should be used in clinical
practice (ie, personalized approach) because, by adapting the dose
according to the renal function, one may avoid side-effects and drug-
discontinuation.17
5 | LIMITATIONS
This is a post hoc nonprespecified analysis of the EPHESUS trial. In
consequence, these results are prone to bias inherent to secondary
studies and should be regarded as exploratory and hypothesis gener-
ating. Moreover, EPHESUS was not designed with sufficient power to
draw statistical conclusions about subgroups (baseline characteristics
were well balanced between MRA and placebo groups, but they were
not between EF < 40 and EF = 40%). We have addressed this issue by
adjusting for potential confounders. Generally, the absence of signifi-
cant “interactions” in all the studied outcomes, points toward a consis-
tent eplerenone effect regardless of the EF subgroup.
6 | CONCLUSIONS
Eplerenone reduces hospitalizations and mortality in patients with EF
of 40% similarly to patients with EF < 40%. These findings suggest
that MI patients with EF in the “mid-range zone” may also benefit
from MRA therapy which might help clinicians in their treatment
decisions.
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